MNG is driven to help our healthcare partners, patients, and families find the answers they need when it comes to a diagnosis. MNG has solutions allowing economical reflex options to further investigate negative or inconclusive results.
No-cost familial testing for qualifying variants found in NGS and single gene testing performed at MNG.
NGS panels are useful diagnostic tools, but they fail to identify the cause of disease in a significant percentage of cases. When further testing is required, MNG makes it easy to add WES to the existing proband sample.
Complete data re-evaluation, not just classification updates to previously reported variants, including copy number changes and newly identified variants.
Whole Exome Sequencing can provide a genetic diagnosis for about 25% of patients, leaving a large portion of those tested with inconclusive results. Whole Genome Sequencing allows assessment of noncoding genomic regions, while transcriptome analysis, applied along with MNG Exome™ or MNGenome® testing allows for functional assessment of variants affecting regulatory regions.
April 9, 2018
MNG Laboratories is pleased to announce the signing of several key international distributor agreements in Asia, Latin America and Eastern Europe.